Streinu-Cercel A.,National Institute For Infectious Diseases Prof Dr Matei Bals |
Streinu-Cercel A.,Carol Davila University of Medicine and Pharmacy |
Sandulescu O.,National Institute For Infectious Diseases Prof Dr Matei Bals |
Sandulescu O.,Carol Davila University of Medicine and Pharmacy |
And 30 more authors.
GERMS | Year: 2017
Background HCV direct-acting antivirals (DAAs) have made treatment easier for both patients and healthcare practitioners, but have also brought new challenges in terms of patient management and monitoring prior to, during, and after treatment. Methods To sum up and unify the clinical experience of Romanian DAA prescribing physicians, we have organized a Consensus Meeting in November 2016 in Bucharest, Romania. Consensus Statement The Consensus Meeting has provided expert answers to ten significant questions regarding HCV infection, namely: How do we diagnose patients with HCV infection? How do we stage liver disease in patients with HCV infection? How do we monitor patients with HCV infection prior to treatment? Which patients with HCV infection do we treat? When do we start treatment for HCV infection? What regimens do we use for treating HCV infection? How do we monitor patients with HCV infection during treatment? What adverse events should we expect during treatment of HCV infection and how do we prevent/manage them? How do we monitor patients with HCV infection after treatment? How do we expect the landscape of HCV to change in the following years?. © GERMS 2017.
Dinu S.,Cantacuzino National Institute of Research Development for Microbiology and Immunology |
Dinu S.,University of Bucharest |
Pnculescu-Gtej I.R.,Cantacuzino National Institute of Research Development for Microbiology and Immunology |
Florescu S.A.,Clinical Hospital Of Infectious And Tropical Diseases Dr Victor Babes |
And 8 more authors.
Travel Medicine and Infectious Disease | Year: 2015
Background: Dengue fever is the commonest arthropod-borne infection worldwide. In recent years, rapid growth in global air travel has resulted in a considerable increase in the incidence of imported cases. In Romania it is now the second most frequent cause for hospitalization (after malaria) in patients arriving from tropical regions. Methods: Serological and molecular diagnostics were applied to samples obtained between 2008 and 2013 from travelers with suspected dengue. Molecular typing was performed by RT-PCR followed by sequencing of the E-NS1 junction. Results: Twelve of 37 suspected cases were confirmed and three remained probable. The infections were acquired in endemic regions in Asia, Africa and in Europe (Madeira Island). Dengue virus nucleic acid was detected and sequenced in nine cases. Phylogenetic analysis indicated that the viruses were of genotypes I and V of serotype 1, cosmopolitan genotype of serotype 2 and genotypes I and III of serotype 3. Conclusions: Romanian tourists traveling to dengue-endemic countries are at risk of acquiring dengue infection. Appropriate prevention measures prior to travel and upon return should be taken, particularly as the dengue secondary vector Aedes albopictus is now established in Bucharest. © 2014 Elsevier Ltd. All rights reserved.